Targeted cancer therapy

By | April 28, 2012

Targeted therapy of colorectal cancer, molecular targeted therapy Erbitux officially listed in China. Erbitux was first used in China to conventional chemotherapy drugs (irinotecan) in advanced resistant colorectal cancer treatment. For the treatment of advanced colorectal cancer are not many effective drugs, so there is no doubt Erbitux in colorectal cancer patients in China will bring new treatment options.
In cancer patients often find that prostaglandin E2 (PGE2) levels increased, so non-steroidal anti-inflammatory drugs, including selective cyclooxygenase-2 (cox-2) inhibitors are considered the most promising treatment for rectal cancer chemotherapy agents. However, their long-term use will be limited by a number of severe illness, these symptoms are considered general decline in the level of prostaglandin-related.
Leading cancer experts, the Chinese Academy of Engineering Professor Sun Yan said: "Compared with traditional chemotherapy, Erbitux such molecular targeted therapy to some extent, some biological, like precision-guided missile that can hit the tumor cells to normal relatively little effect on cells; Erbitux is also in the mechanism of action different from traditional chemotherapy drugs, so as not traditional chemotherapy side effects, but also for traditional chemotherapy drugs such as irinotecan-resistant patients with advanced metastatic colorectal cancer, love Erbitux is also achieved satisfactory results, some patients can reverse the resistance of the situation. "
Targeted therapy of colorectal cancer incidence of colorectal cancer talking about the situation in China, Professor Sun Yan said with deep concern: the growth of colorectal cancer is very fast, especially in some large cities, which is higher living standards, diet structure changes are closely related. Should therefore be strongly advocated to maintain the traditional diet, control of excessive fat intake, eat more fruits and vegetables, regular abdominal B-ultrasound and digital rectal examination, colorectal cancer can be prevented.
Canada Masako Nakanishi in two mouse models of intestinal cancer chemotherapy were evaluated in the terminal PGE2 synthase in the synthesis of microbody enzymes (mPEGS-1) is effective. mPEGS-1 that is responsible for generating PGE2. The first report of the Apc mutant mice mPEGS-1 gene deletion significantly and continuing to inhibition of intestinal cancer, growing up to 66%, while the inhibition of large tumor almost 95%. This effect is not heterozygous loss of Apc and -catenin activation in. According to the results of CD31 immunohistochemistry further found that, mPEGS-1 with large tumor defects in the structure of vascular abnormalities. mPEGS-1 in the absence of reduction of tumor-like abnormalities of the former foci (ACF) of the size and quantity. More importantly, mPEGS-1 would block the ACF deletion of -catenin accumulation in the nucleus, which confirmed cancer of -catenin is a cancer derived PGE2, a key signaling pathway in the target.
Targeted cancer drugs, research shows the use of mPEGS-1 target genes as a cancer chemotherapy, the feasibility of the method relative to traditional non-solid-inflammatory drugs and selective cox-2 inhibitor side effects of drug therapy to improve more promising.

Leave a Reply

Your email address will not be published. Required fields are marked *